Spesolimab improves patient‐reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study

Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the Effisayil™ 1 study, spesolimab, an anti‐interleukin‐36 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares.

[1]  K. Eyerich,et al.  Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey , 2022, American Journal of Clinical Dermatology.

[2]  M. Lebwohl,et al.  Trial of Spesolimab for Generalized Pustular Psoriasis. , 2021, The New England journal of medicine.

[3]  M. Lebwohl,et al.  Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare , 2021, BMJ Open.

[4]  B. Strober,et al.  Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists , 2021, Dermatology and Therapy.

[5]  M. Schaarschmidt,et al.  Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study , 2021, Dermatologic therapy.

[6]  A. Slade,et al.  The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders , 2020, Journal of Patient-Reported Outcomes.

[7]  D. Revicki,et al.  Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis , 2020, The Journal of dermatological treatment.

[8]  H. Bachelez.  Pustular Psoriasis: The Dawn of a New Era , 2020, Acta dermato-venereologica.

[9]  B. Strober,et al.  US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry , 2020, The Journal of dermatological treatment.

[10]  M. Lebwohl,et al.  An update on generalized pustular psoriasis , 2019, Expert review of clinical immunology.

[11]  M. Akiyama,et al.  Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP , 2018, The Journal of dermatology.

[12]  T. Bieber,et al.  Successful treatment with interleukin‐17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations , 2018, The Journal of dermatology.

[13]  H. Nakagawa,et al.  Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study , 2018, The Journal of dermatology.

[14]  C. Gabay,et al.  Regulation and function of interleukin‐36 cytokines , 2018, Immunological reviews.

[15]  D. Mennerich,et al.  Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies , 2017, mAbs.

[16]  H. Nakagawa,et al.  Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J) , 2016, The Journal of dermatology.

[17]  L. Naldi,et al.  European consensus statement on phenotypes of pustular psoriasis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  A. Gnanasakthy,et al.  Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development , 2017, The Patient - Patient-Centered Outcomes Research.

[19]  H. Nakagawa,et al.  Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase III open‐label multicenter Japanese study , 2016, The Journal of dermatology.

[20]  A. Finlay,et al.  Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data , 2015, Dermatology.

[21]  N. Lai,et al.  Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia , 2014, International journal of dermatology.

[22]  M. Lebwohl,et al.  Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2012, Journal of the American Academy of Dermatology.

[23]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[24]  J. Ortonne,et al.  Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy , 2011, The British journal of dermatology.

[25]  A. Gottlieb,et al.  Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks , 2007, The British journal of dermatology.

[26]  D. Cella,et al.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[27]  I. Stiell,et al.  Clinically important change in the visual analog scale after adequate pain control. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[28]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.